Aurélien Godinat

Aurélien Godinat

Auto-generated profile, based on publicly available information

Aurélien Godinat

Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London, W12 0BZ, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
NPNattawadee Panyain
Nattawadee Panyain
AGAurélien Godinat
Aurélien Godinat
ATAditya Raymond Thawani
Aditya Raymond Thawani
SLSofia Lachiondo-Ortega
Sofia Lachiondo-Ortega
KMKatie Mason
Katie Mason
ETEdward W. Tate
Edward W. Tate
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme (DUB), is a potential drug target in various cancers, and liver and lung fibrosis. However, bona fide functions and substrates of UCHL1 remain poorly understood. Herein, we report the characterization of UCHL1 covalent inhibitor MT16-001 based on a thiazole cyanopyrrolidine scaffold. In combination with chemical proteomics, a closely related activity-based probe (MT16-205) was used to generate a comprehensive quantitative profile for on- and off-targets at endogenous cellular abundance. Both compounds are selective for UCHL1 over other DUBs in intact cells but also engage a range of other targets with good selectivity over the wider proteome, including aldehyde dehydrogenases, redox-sensitive Parkinson's disease related protein PARK7, and glutamine amidotransferase. Taken together, these results underline the importance of robust profiling of activity-based probes as chemical tools and highlight the cyanopyrrolidine warhead as a versatile platform for liganding diverse classes of protein with reactive cysteine residues which can be used for further inhibitor screening, and as a starting point for inhibitor development.

31 October 2019 in ChemRxiv
Verified
Preprint
Open access
NPNattawadee Panyain
Nattawadee Panyain
AGAurélien Godinat
Aurélien Godinat
TLThomas Lanyon-Hogg
Thomas Lanyon-Hogg
SLSofia Lachiondo-Ortega
Sofia Lachiondo-Ortega
EWEdward J. Will
Edward J. Will
ETEdward Tate
Edward Tate
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a deubiquitylating enzyme which is proposed as a potential therapeutic target in neurodegeneration, cancer, and liver and lung fibrosis. Herein we report the discovery of the most potent and selective UCHL1 probe (IMP-1710) to date based on a covalent inhibitor scaffold and apply this probe to identify and quantify target proteins in intact human cells. IMP-1710 stereoselectively labels the catalytic cysteine of UCHL1 at low nanomolar concentration in cells, and we show that a previously claimed UCHL1 inhibitor (LDN-57444) fails to engage UCHL1 in cells. We further demonstrate that potent UCHL1 inhibitors block pro-fibrotic responses in a cellular model of idiopathic pulmonary fibrosis, supporting a potential therapeutic role for UCHL1 inhibition and providing a basis for future therapeutic development of selective UCHL1 inhibitors.